Pathogenesis of Atypical Hemolytic Uremic Syndrome

Overview

Journal J Atheroscler Thromb

Date 2018 Nov 6

PMID 30393246

Citations 36

Authors

Yoko Yoshida

Hideki Kato

Yoichiro Ikeda

Masaomi Nangaku

Affiliations

Soon will be listed here.

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a type of thrombotic microangiopathy (TMA) defined by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure. aHUS is caused by uncontrolled complement activation in the alternative pathway (AP). A variety of genetic defects in complement-related factors or acquired autoantibodies to the complement regulators have been found in 50 to 60% of all cases. Recently, however, the classification and diagnosis of aHUS are becoming more complicated. One reason for this is that some factors, which have not been regarded as complement-related factors, have been reported as predisposing factors for phenotypic aHUS. Given that genotype is highly correlated with the phenotype of aHUS, careful analysis of underlying genetic abnormalities or acquired factors is needed to predict the prognosis or to decide an optimal treatment for the disease. Another reason is that complement dysregulation in the AP have also been found in a part of other types of TMA such as transplantation-related TMA and pregnancy-related complication. Based on these findings, it is now time to redefine aHUS according to the genetic or acquired background of abnormalities.Here, we review the pathogeneses and the corresponding phenotypes of aHUS and complement-related TMAs.

Citing Articles

A Case of Atypical Hemolytic Uremic Syndrome With a Complement Factor I Mutation Triggered by a Femoral Neck Fracture.

Kano T, Io H, Sasaki Y, Muto M, Muto S, Ogiwara K Nephrology (Carlton). 2025; 30(3):e70010.

PMID: 40001340 PMC: 11861886. DOI: 10.1111/nep.70010.

The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome.

Jang J, Han B, Jung J, Russo P, Kulasekararaj A BioDrugs. 2025; 39(2):281-295.

PMID: 39982653 PMC: 11906501. DOI: 10.1007/s40259-025-00707-3.

Atypical hemolytic uremic syndrome with a variant following COVID-19: a case report.

Ando M, Kubota K, Kadowaki S, Kawamoto M, Kawamoto N, Okamoto H Front Pediatr. 2025; 13:1507727.

PMID: 39917338 PMC: 11799235. DOI: 10.3389/fped.2025.1507727.

Severe pregnancy-associated atypical hemolytic uremia syndrome in the context of the COVID-19 pandemic: a novel survival case report.

Yang Y, Li X, Yuan H, Xiong J, Li P, Wang Z BMC Pregnancy Childbirth. 2025; 25(1):93.

PMID: 39885445 PMC: 11780773. DOI: 10.1186/s12884-025-07212-z.

Diacylglycerol Kinases and Its Role in Lipid Metabolism and Related Diseases.

Liu Y, Yang Z, Zhou X, Li Z, Hideki N Int J Mol Sci. 2024; 25(23).

PMID: 39684917 PMC: 11643042. DOI: 10.3390/ijms252313207.

References

Jokiranta T, Hellwage J, Koistinen V, Zipfel P, Meri S . Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem. 2000; 275(36):27657-62. DOI: 10.1074/jbc.M002903200. View

Levy G, Nichols W, Lian E, Foroud T, McClintick J, McGee B . Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001; 413(6855):488-94. DOI: 10.1038/35097008. View

Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M . Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A. 2002; 99(18):11902-7. PMC: 129366. DOI: 10.1073/pnas.172277399. View

Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S . Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest. 2003; 111(8):1181-90. PMC: 152934. DOI: 10.1172/JCI16651. View

Sanchez-Corral P, Gonzalez-Rubio C, Rodriguez de Cordoba S, Lopez-Trascasa M . Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol. 2004; 41(1):81-4. DOI: 10.1016/j.molimm.2004.01.003. View

McRae J, Duthy T, Griggs K, Ormsby R, Cowan P, Cromer B . Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J Immunol. 2005; 174(10):6250-6. DOI: 10.4049/jimmunol.174.10.6250. View

Heinen S, Sanchez-Corral P, Jackson M, Strain L, Goodship J, Kemp E . De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat. 2006; 27(3):292-3. DOI: 10.1002/humu.9408. View

Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P . Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006; 108(4):1267-79. PMC: 1895874. DOI: 10.1182/blood-2005-10-007252. View

Richards A, Liszewski M, Kavanagh D, Fang C, Moulton E, Fremeaux-Bacchi V . Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol. 2006; 44(1-3):111-22. DOI: 10.1016/j.molimm.2006.07.004. View

10.

Ferreira V, Herbert A, Hocking H, Barlow P, Pangburn M . Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol. 2006; 177(9):6308-16. DOI: 10.4049/jimmunol.177.9.6308. View

11.

Venables J, Strain L, Routledge D, Bourn D, Powell H, Warwicker P . Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med. 2006; 3(10):e431. PMC: 1626556. DOI: 10.1371/journal.pmed.0030431. View

12.

Goicoechea de Jorge E, Harris C, Esparza-Gordillo J, Carreras L, Arranz E, Garrido C . Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2006; 104(1):240-5. PMC: 1765442. DOI: 10.1073/pnas.0603420103. View

13.

Zipfel P, Edey M, Heinen S, Jozsi M, Richter H, Misselwitz J . Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007; 3(3):e41. PMC: 1828695. DOI: 10.1371/journal.pgen.0030041. View

14.

Hageman G, Hancox L, Taiber A, Gehrs K, Anderson D, Johnson L . Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med. 2007; 38(8):592-604. PMC: 1905836. View

15.

Jozsi M, Strobel S, Dahse H, Liu W, Hoyer P, Oppermann M . Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood. 2007; 110(5):1516-8. DOI: 10.1182/blood-2007-02-071472. View

16.

Kavanagh D, Richards A, Noris M, Hauhart R, Liszewski M, Karpman D . Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol. 2007; 45(1):95-105. DOI: 10.1016/j.molimm.2007.05.004. View

17.

Schuster V, Hugle B, Tefs K . Plasminogen deficiency. J Thromb Haemost. 2007; 5(12):2315-22. DOI: 10.1111/j.1538-7836.2007.02776.x. View

18.

Jozsi M, Licht C, Strobel S, Zipfel S, Richter H, Heinen S . Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2007; 111(3):1512-4. DOI: 10.1182/blood-2007-09-109876. View

19.

Fakhouri F, Jablonski M, Lepercq J, Blouin J, Benachi A, Hourmant M . Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood. 2008; 112(12):4542-5. DOI: 10.1182/blood-2008-03-144691. View

20.

Fremeaux-Bacchi V, Miller E, Liszewski M, Strain L, Blouin J, Brown A . Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008; 112(13):4948-52. PMC: 2597601. DOI: 10.1182/blood-2008-01-133702. View